MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral infection on the point-of-need platform MeMed Key® HAIFA, Israel; BOSTON, MA; January 10th, 2022 – MeMed, a leader in host response technologies, today announces a $93 million […]